ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Malaria remains a major global health challenge, with current vaccines providing only limited reductions in case numbers. This study introduces an innovative approach that utilizes engineered Escherichia coli to bioconjugate and assemble the pre-erythrocytic circumsporozoite protein-derived RTS,S antigen and the sexual-stage Pfs47 subdomain into biopolymer particles (BPs), generating the dual-antigen Pfs47-RTS,S-BP vaccine. Compared to single-antigen BPs, the fused Pfs47-RTS,S-BP formulation shows synergistic enhancement in immunogenicity and protective efficacy. Pfs47‑RTS,S‑BP retains its physical properties and antigenicity after storage at 37°C. Although functional in vivo assessment of these thermostable formulations has not yet been performed, the findings indicate promising thermostability that could help overcome cold‑chain limitations in malaria‑endemic regions. Pfs47-RTS,S-BP induces durable antibody and T cell responses alongside crucial liver-resident memory T cells for frontline defence. Vaccine-induced antibodies efficiently neutralize sporozoites and inhibit parasite transmission. Pfs47-RTS,S-BP generates RTS,S-specific antibody levels 5.3-fold higher than the protective thresholds of the current RTS,S/AS01 vaccine. The Pfs47-RTS,S-BP formulation also achieves 80.4% protection against mosquito bite challenge and 68.15% transmission-reducing activity, demonstrating strong potential as a robust, dual-stage malaria vaccine candidate. Overall, this work underscores the potential of Pfs47‑RTS, S‑BP to overcome key limitations of current vaccines and to substantially advance global malaria control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.